Cochrane · systematic review · CD005000
Aripiprazole alone or in combination for acute mania
Brown, R, Taylor, MJ, Geddes, J · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 33.3%Moderate 5 · 41.7%High 3 · 25%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Aripiprazole versus placebo for an acute manic or mixed episode
Population: patients with an acute manic or mixed episode
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in YMRS from baseline at three weeks Young Mania Rating Scale (YMRS): an 11‐item questionnaire to assess the severity of core symptoms of mania. Scale from 0 to 60 Aripiprazole vs placebo | no estimate extracted | 1819 participants | Moderate |
≥ 50% decrease in total YMRS from baseline at three weeks Young Mania Rating Scale (as above) Aripiprazole vs placebo | RR 1.7 [1.23, 2.34] | 1230 participants | Moderate |
Numbers completing double‐blind treatment Number of participants Aripiprazole vs placebo | RR 1.03 [0.95, 1.12] | 2216 participants | Moderate Downgraded: imprecision, inconsistency |
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects Aripiprazole vs placebo | RR 3.28 [1.82, 5.91] | 730 participants | High |
Akathisia Participant report Aripiprazole vs placebo | RR 3.16 [2.25, 4.43] | 2305 participants | High |
Nausea Participant report Aripiprazole vs placebo | RR 1.5 [1.2, 1.88] | 2305 participants | High |
Aripiprazole versus other drug treatment for an acute manic or mixed episode
Population: patients with an acute manic or mixed episode
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in YMRS from baseline at week three Young Mania Rating Scale: an 11‐item questionnaire to assess the severity of the core symptoms of mania. Scale from 0 to 60 Aripiprazole vs other drug treatment | no estimate extracted | 972 participants | Moderate Downgraded: imprecision |
≥ 50% decrease in YMRS from baseline at week three Young Mania Rating Scale (YMRS): as above Aripiprazole vs other drug treatment | RR 1.12 [0.77, 1.63] | 990 participants | Moderate Downgraded: imprecision |
Numbers completing the trial (at end of week three) Number of participants Aripiprazole vs other drug treatment | RR 1.13 [1.03, 1.24] | 994 participants | Low Downgraded: imprecision, inconsistency |
Barnes Akathisia Scale LOCF at week 12 A physician‐assessed rating scale to assess the severity of drug‐induced akathisia Scale from 0 to 14 Aripiprazole vs other drug treatment | no estimate extracted | 646 participants | Low Downgraded: imprecision, inconsistency |
Abnormal Involuntary Movement Scale LOCF at week 12 A physician‐administered rating scale with 12 items to measure tardive dyskinesia Scale from 0 to 40 Aripiprazole vs other drug treatment | no estimate extracted | 634 participants | Low Downgraded: imprecision, inconsistency |
Simpson Angus Scale LOCF at week 12 A physician‐administered rating scale to measure drug‐induced Parkinsonism Scale from 0 to 40. Aripiprazole vs other drug treatment | no estimate extracted | 646 participants | Low Downgraded: imprecision, inconsistency |